Diagnostics (May 2023)

[<sup>18</sup>F]FES PET Resolves the Diagnostic Dilemma of COVID-19-Vaccine-Associated Hypermetabolic Lymphadenopathy in ER-Positive Breast Cancer

  • Munenobu Nogami,
  • Tetsuya Tsujikawa,
  • Hiroyuki Maeda,
  • Nobuyuki Kosaka,
  • Mizuho Takahashi,
  • Naoki Kinoshita,
  • Tetsuya Mori,
  • Akira Makino,
  • Yasushi Kiyono,
  • Takamichi Murakami,
  • Takanori Goi,
  • Hidehiko Okazawa

DOI
https://doi.org/10.3390/diagnostics13111851
Journal volume & issue
Vol. 13, no. 11
p. 1851

Abstract

Read online

Coronavirus disease (COVID-19) vaccination is known to cause a diagnostic dilemma due to false-positive findings on [18F]FDG PET in vaccine-associated hypermetabolic lymphadenopathy. We present two case reports of women with estrogen-receptor (ER)-positive cancer of the breast who were vaccinated for COVID-19 in the deltoid muscle. [18F]FDG positron emission tomography (PET) demonstrated primary breast cancer and multiple axillary lymph nodes with increased [18F]FDG uptake, diagnosed as vaccine-associated [18F]FDG-avid lymph nodes. Subsequent [18F]FES PET revealed single axillary lymph node metastasis in the vaccine-associated [18F]FDG-avid lymph nodes. To the best of our knowledge, this is the first study showing the usefulness of [18F]FES PET in diagnosing axillary lymph node metastasis in COVID-19-vaccinated patients harboring ER-positive breast cancer. Thus, [18F]FES PET has potential applications in the detection of true-positive metastatic lymph nodes in patients with ER-positive breast cancer regardless of the ipsilateral or contralateral side, who have received COVID-19 vaccination.

Keywords